Roughly one year after securing €5 million ($6.5 million) in venture capital funding, Spanish oligonucleotide drug developer nLife Therapeutics has set its sights on initiating non-human primate testing of its core intranasal delivery technology, which it hopes will spur licensing deals with bigger industry players, according to the firm's top executive.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.